Radiotherapy combined with gemcitabine and oxaliplatin in pancreatic cancer cells

Translational Oncology

Volumn 1, Issue 1, 2008, Pages 36-43

  Morgan, Meredith A ^a   Meirovitz, Amichay ^a   Davis, Mary A ^a   Kollar, Laura E ^a   Hassan, Maria C ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 60849091320     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.07106     Document Type: Article

References (26)

1. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, et al. (2001). Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 19, 4202-4208.
2. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, and Schilsky R (1999). An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85, 1261-1268.
3. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, and Ben-Josef E (2007). Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 68, 801-808.
4. Lawrence TS, Chang EY, Hahn TM, Hertel LW, and Shewach DS (1996). Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 34, 867-872.
5. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, et al. (1981). Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48, 1705-1710.
6. Philip PA, Zalupski MM, Vaitkevicius VK, Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D, and Shields AF (2001). Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 92, 569-577.
7. Symon Z, Davis M, McGinn CJ, Zalupski MM, and Lawrence TS (2002). Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 53, 140-145.
8. Muler JH, McGinn CJ, Normolle D, Lawrence T, Brown D, Hejna G, and Zalupski MM (2004). Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 22, 238-243.
9. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, Zaniboni A, Ducreux M, Aitini E, Taieb J, et al. (2005). Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23, s3509-3516.
10. Lawrence TS (1988). Ouabain sensitizes tumor cells but not normal cells to radiation. Int J Radiat Oncol Biol Phys 15, 953-958.
11. Fertil B, Dertinger H, Courdi A, and Malaise EP (1984). Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99, 73-84.
12. Chou TC and Talalay P (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22, 27-55.
13. Heinemann V, Hertel LW, Grindey GB, and Plunkett W (1988). Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine. Cancer Res 48, 4024-4031.
14. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, et al. (2000). Oxaliplatininduced damage of cellular DNA. Mol Pharmacol 58, 920-927.
15. Pappas P, Mavroudis D, Nikolaidou M, Georgoulias V, and Marselos M (2006). Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. Anticancer Drugs 17, 1185-1191.
16. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J, and Lawrence TS (2005). Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65, 6835-6842.
17. Ewald B, Sampath D, and Plunkett W (2007). H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 6, 1239-1248.
18. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, and Benson AB III (2000). Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 18, 3384-3389.
19. Wilkowski R, Thoma M, Bruns C, Wagner A, and Heinemann V (2006). Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP 7, 349-360.
20. Safran H, Dipetrillo T, Iannitti D, Quirk D, Akerman P, Cruff D, Cioffi W, Shah S, Ramdin N, and Rich T (2002). Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a phase I trial. Int J Radiat Oncol Biol Phys 54, 137-141.
21. Mishra G, Butler J, Ho C, Melin S, Case LD, Ennever PR, Magrinat GC, Bearden JD, Minotto DC, Howerton R, et al. (2005). Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. Am J Clin Oncol 28, 345-350.
22. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25, 1960-1966.
23. Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D, Miner T, Martel D, Cioffi W, Remis M, et al. (1999). Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 28, 570-575.
24. Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, et al. (2001). Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol 29, 9-18.
25. Crane CH, Antolak JA, Rosen II, Forster KM, Evans DB, Janjan NA, Charnsangavej C, Pisters PW, Lenzi R, Papagikos MA, et al. (2001). Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 30, 123-132.
26. Scalliet P, Goor C, Galdermans D, Meerbeek JV, Groen HJ, Leest AHDVd, Westerink H, Jungnelius U, and Turrisi L (1998). Gemcitabine with thoracic radiotherapy-a phase II pilot study in chemonaive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17, 499a. Abstract # 1923.